Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) Operating Expenses (2016 - 2026)

Champions Oncology has reported Operating Expenses over the past 17 years, most recently at $16.8 million for Q1 2026.

  • For Q1 2026, Operating Expenses rose 34.25% year-over-year to $16.8 million; the TTM value through Jan 2026 reached $60.6 million, up 15.81%, while the annual FY2025 figure was $52.4 million, 8.9% down from the prior year.
  • Operating Expenses for Q1 2026 was $16.8 million at Champions Oncology, up from $14.8 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $16.8 million in Q1 2026 and troughed at $12.4 million in Q1 2022.
  • A 5-year average of $14.2 million and a median of $14.3 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: fell 15.75% in 2024 and later skyrocketed 34.25% in 2026.
  • Year by year, Operating Expenses stood at $14.3 million in 2022, then fell by 5.23% to $13.5 million in 2023, then dropped by 5.7% to $12.8 million in 2024, then increased by 16.41% to $14.8 million in 2025, then rose by 13.37% to $16.8 million in 2026.
  • Business Quant data shows Operating Expenses for CSBR at $16.8 million in Q1 2026, $14.8 million in Q4 2025, and $14.5 million in Q3 2025.